Hospital General Universitario De Castellon
- Address
- lock Available on a paid plan
Neoplasms – Prostate Cancer Research
The urology department at Hospital General Universitario De Castellon is conducting studies on high‑risk localized or locally advanced prostate cancer, aiming to improve surgical outcomes and long‑term disease control.
- Combination therapy with apalutamide and androgen deprivation therapy
- Use of conventional and PSMA PET imaging to guide treatment
- Focus on pathological complete response and metastasis‑free survival
With 23 investigators involved, the site is evaluating whether adding apalutamide to standard therapy can raise cure rates while monitoring safety.
Nervous System Disorders – Narcolepsy Study
A trial at the same facility explores the effect of switching patients with narcolepsy from high‑sodium oxybate to the newer formulation XYWAV, with particular attention to 24‑hour ambulatory blood pressure.
- Blood pressure monitoring after medication switch
- Assessment of daytime sleepiness and nighttime sleep quality
- Evaluation of safety and tolerability of reduced‑sodium therapy
The study involves a multidisciplinary team and seeks to demonstrate that the new treatment can maintain symptom control while lowering cardiovascular risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 85 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International5trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital General Universitario De Castellon
lock Showing 1 of 49 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma | LETI Pharma S.L.U. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Mitomycin | 5 | Unknown | 2022-02-14 | 2026-05-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.